Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis.

[1]  E. Bleecker,et al.  Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. , 2013, The Journal of allergy and clinical immunology.

[2]  Johny Verschakelen,et al.  Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial , 2013, Thorax.

[3]  E. R. Sutherland,et al.  A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.

[4]  P. O'Byrne,et al.  Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  Tonya S. King,et al.  Cluster Analysis of Obesity and Asthma Phenotypes , 2012, PloS one.

[6]  I. Pavord,et al.  Stability of inflammatory phenotypes in asthma , 2012, Thorax.

[7]  R. Hancox,et al.  Asthma phenotypes: Consistency of classification using induced sputum , 2012, Respirology.

[8]  Mario Castro,et al.  Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. , 2011, The Journal of allergy and clinical immunology.

[9]  D. Jarvis,et al.  Identifying adult asthma phenotypes using a clustering approach , 2011, European Respiratory Journal.

[10]  Jodie L Simpson,et al.  Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. , 2011, The Journal of allergy and clinical immunology.

[11]  Tonya S. King,et al.  A trial of clarithromycin for the treatment of suboptimally controlled asthma. , 2010, The Journal of allergy and clinical immunology.

[12]  P. Paggiaro,et al.  Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  Deborah A Meyers,et al.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. , 2010, The Journal of allergy and clinical immunology.

[14]  C. Lemière,et al.  Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples. , 2010, The Journal of allergy and clinical immunology.

[15]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[16]  J. Cowan,et al.  Effects of steroid therapy on inflammatory cell subtypes in asthma , 2009, Thorax.

[17]  M. Weatherall,et al.  Distinct clinical phenotypes of airways disease defined by cluster analysis , 2009, European Respiratory Journal.

[18]  E. Kerwin,et al.  A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. , 2009, American journal of respiratory and critical care medicine.

[19]  D. Denning,et al.  Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. , 2009, American journal of respiratory and critical care medicine.

[20]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[21]  R. Scott,et al.  Clarithromycin targets neutrophilic airway inflammation in refractory asthma. , 2008, American journal of respiratory and critical care medicine.

[22]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[23]  Mario Castro,et al.  Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. , 2008, The Journal of allergy and clinical immunology.

[24]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[25]  E. Israel,et al.  Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. , 2005, The Journal of allergy and clinical immunology.

[26]  A. Zwinderman,et al.  "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. , 2004, American journal of respiratory and critical care medicine.

[27]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[28]  S. Spector,et al.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. , 2000, American journal of respiratory and critical care medicine.

[29]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[30]  J. H. Ward.  Hierarchical Grouping to Optimize an Objective Function , 1963 .

[31]  H. Kaiser.  The varimax criterion for analytic rotation in factor analysis , 1958 .